Lipid Accumulation Product is an Effective Predictor of Metabolic Syndrome in Non-obese Women with Polycystic Ovary Syndrome

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jan 25

PMID 38269246

Authors

Wenju Han

Meiwei Zhang

Haiyan Wang

Yitian Yang

Lei Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the correlation of lipid accumulation product (LAP) with metabolic syndrome (MS) and to assess the predictive value of LAP for MS risk in polycystic ovary syndrome (PCOS) with different body mass index (BMI).

Methods: A total of 242 PCOS patients and 150 controls were recruited and divided into normal-weight, overweight, and obese groups, then further divided into MS and without MS subgroups. Clinical and anthropometric variables and laboratory results were recorded. LAP was calculated from waist circumference (WC) and triglyceride using sex-specific formulae. Logistic regression analysis and receiver operating characteristic (ROC) curve were applied to determine and analyze the predictive value of LAP for MS.

Results: The prevalence of MS among PCOS patients was 45.04%, which was significantly higher than that of the controls (10%). Stratified by BMI, the incidence of MS in the normal-weight, overweight, and obese PCOS groups were 15.58%, 41.43%, and 71.58%, respectively. Logistic regression analysis indicated that LAP was an independent risk factor for MS in both normal-weight and overweight groups; however, the results were not significant in the obese group. ROC curve analysis showed that LAP had an outstanding discrimination index for MS in normal-weight (AUC=0.960, cut-off value=42.5) and overweight (AUC=0.937, cut-off value=47.93) PCOS patients, with a sensitivity of 0.917/0.931 (normal-weight/overweight) and a specificity of 0.969/0.854 (normal-weight/overweight), respectively.

Conclusion: Normal-weight and overweight PCOS patients also have a fairly high incidence of MS and should receive as much attention as obese patients. Compared to applying multiple clinical indicators, LAP is more convenient and facilitates acquiring early and accurate diagnoses of MS among non-obese PCOS patients using fewer MS markers.

Citing Articles

Predicting metabolic syndrome by lipid accumulation product, visceral adiposity index and body roundness index in Brazilian rural workers.

Ferreira J, Libardi M, do Prado C, Zandonade E, Bezerra O, Salaroli L BMC Public Health. 2025; 25(1):544.

PMID: 39930422 PMC: 11812240. DOI: 10.1186/s12889-025-21624-8.

Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology.

Valerio G, Di Bonito P, Calcaterra V, Cherubini V, Corica D, de Sanctis L Ital J Pediatr. 2024; 50(1):205.

PMID: 39380079 PMC: 11463079. DOI: 10.1186/s13052-024-01767-x.

The Lipid Accumulation Product Index (LAP) and the Cardiometabolic Index (CMI) Are Useful for Predicting the Presence and Severity of Metabolic Syndrome in Adult Patients with Obesity.

Tamini S, Bondesan A, Caroli D, Sartorio A J Clin Med. 2024; 13(10).

PMID: 38792386 PMC: 11122168. DOI: 10.3390/jcm13102843.

References

Carmina E, Lobo R . Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important than the Rotterdam Phenotype in Influencing the Metabolic Status. Diagnostics (Basel). 2022; 12(10). PMC: 9600591. DOI: 10.3390/diagnostics12102313. View

Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia D . Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005; 106(1):131-7. DOI: 10.1097/01.AOG.0000167408.30893.6b. View

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

Yin Q, Zheng J, Cao Y, Yan X, Zhang H . Evaluation of Novel Obesity and Lipid-Related Indices as Indicators for the Diagnosis of Metabolic Syndrome and Premetabolic Syndrome in Chinese Women with Polycystic Ovary Syndrome. Int J Endocrinol. 2021; 2021:7172388. PMC: 8387166. DOI: 10.1155/2021/7172388. View

Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F . Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007; 92(7):2500-5. DOI: 10.1210/jc.2006-2725. View

Moran L, Misso M, Wild R, Norman R . Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(4):347-63. DOI: 10.1093/humupd/dmq001. View

Li R, Zhang Q, Yang D, Li S, Lu S, Wu X . Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013; 28(9):2562-9. DOI: 10.1093/humrep/det262. View

Wekker V, van Dammen L, Koning A, Heida K, Painter R, Limpens J . Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020; 26(6):942-960. PMC: 7600286. DOI: 10.1093/humupd/dmaa029. View

Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D . Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016; 207:214-219. DOI: 10.1016/j.ejogrb.2016.08.026. View

10.

Zhang X, Zhang M, Zhao Z, Huang Z, Deng Q, Li Y . Geographic Variation in Prevalence of Adult Obesity in China: Results From the 2013-2014 National Chronic Disease and Risk Factor Surveillance. Ann Intern Med. 2019; 172(4):291-293. DOI: 10.7326/M19-0477. View

11.

He H, Feng J, Zhang S, Wang Y, Li J, Gao J . The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2022; 12:773781. PMC: 8766308. DOI: 10.3389/fendo.2021.773781. View

12.

Song Y, Manson J, Meigs J, Ridker P, Buring J, Liu S . Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol. 2007; 100(11):1654-8. PMC: 2098701. DOI: 10.1016/j.amjcard.2007.06.073. View

13.

Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z . Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2013; 121(2):115-8. DOI: 10.1055/s-0032-1333261. View

14.

Sanchez-Garrido M, Tena-Sempere M . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35:100937. PMC: 7115104. DOI: 10.1016/j.molmet.2020.01.001. View

15.

Macut D, Bozic Antic I, Bjekic-Macut J, Panidis D, Tziomalos K, Vojnovic Milutinovic D . Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. Hormones (Athens). 2015; 15(1):35-44. DOI: 10.14310/horm.2002.1592. View

16.

Behboudi-Gandevani S, Amiri M, Yarandi R, Noroozzadeh M, Farahmand M, Rostami Dovom M . The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2017; 88(2):169-184. DOI: 10.1111/cen.13477. View

17.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

18.

Gu Z, Zhu P, Wang Q, He H, Xu J, Zhang L . Obesity and lipid-related parameters for predicting metabolic syndrome in Chinese elderly population. Lipids Health Dis. 2018; 17(1):289. PMC: 6302378. DOI: 10.1186/s12944-018-0927-x. View

19.

Diamanti-Kandarakis E, Papavassiliou A, Kandarakis S, Chrousos G . Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007; 18(7):280-5. DOI: 10.1016/j.tem.2007.07.004. View

20.

Lim S, Kakoly N, Tan J, Fitzgerald G, Bahri Khomami M, Joham A . Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2018; 20(2):339-352. DOI: 10.1111/obr.12762. View